Domain Partners
SelectivePrinceton, NJBiotechnology, Healthcare, PharmaceuticalsLast fund filed December 2014
7 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Domain Partners IX, L.P. | December 2014 | Indefinite | $164M | 6 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
7 partners are named across this firm’s filings, 7 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Brian Halak | Slowing | Biotech & pharma, Medical devices | 7 | 1 |
Classified sectors of Domain Partners’s own portfolio companies, based on 43 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| Lightstone Ventures | 5 | Allay Therapeutics, Kona Medical, MIRAMAR LABS, Tragara Pharmaceuticals, TWELVE |
| Qiming U.S Healthcare | 3 | Kona Medical, TWELVE, WindMIL Therapeutics |
| Stack Infrastructure | 3 | Evofem Biosciences, Orexigen Therapeutics, Sequent Medical |
| Kim Kamdar | Slowing | Biotech & pharma, Digital health, Healthcare services | 7 | 1 |
| Brian Dovey | Quiet | Biotech & pharma, Medical devices, E-commerce & marketplaces | 8 | 0 |
| James Blair | Quiet | Biotech & pharma, AI & machine learning, Education | 11 | 0 |
| Kathleen Schoemaker | Quiet | None listed | 0 | 0 |
| Nicole Vitullo | Quiet | Biotech & pharma, AI & machine learning | 8 | 0 |
| Nimesh Shah | Quiet | Medical devices, AI & machine learning, Biotech & pharma | 8 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Domain Partners’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| 3 |
| Cotera, Sequent Medical, TWELVE |
| IPI Partners | 2 | Evofem Biosciences, Orexigen Therapeutics |
| Polaris Partners | 2 | aTYR PHARMA, Fractyl Health |
| Sofinnova Healthquest Partners | 2 | ALIMERA SCIENCES, Trice Medical |
| Versant Venture Capital | 2 | Sequent Medical, ZYGA TECHNOLOGY |
| Versant Venture V AIV | 2 | Sequent Medical, ZYGA TECHNOLOGY |
| Versant Voyageurs | 2 | Sequent Medical, ZYGA TECHNOLOGY |
| 270 Healthcare Growth | 1 | SERA PROGNOSTICS |
| ARCH Venture Partners | 1 | SonoThera |
| Baird Venture Partners | 1 | Allay Therapeutics |
| Chemistry Ventures | 1 | aTYR PHARMA |
| Longitude Capital | 1 | Esperion Therapeutics |
A shared board seat: a company where filings name a Domain Partners partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.